Nasal Polyps

Table of Contents

1. What Nasal Polyps Are
2. Disease Associations
3. Symptoms
4. Diagnosis
5. Medical Treatment
6. Biologic Therapy
7. Surgery (FESS)
8. Recurrence and Long-Term Management
9. Key Research Papers
10. Connections
11. Featured Videos

What Nasal Polyps Are

Nasal polyps are benign, teardrop-shaped, soft tissue growths that arise from the lining of the nasal cavity and paranasal sinuses. They are not tumors and do not become cancerous — but they can grow large enough to completely obstruct the nasal passages and sinuses, causing significant disability.

Polyps form as a result of type 2 eosinophilic inflammation — an immune response driven by cytokines IL-4, IL-5, and IL-13, with elevated immunoglobulin E (IgE) and tissue eosinophilia. They typically arise from the ethmoid sinuses (between the eyes) and grow into the nasal cavity. The vast majority are bilateral (both sides) — a polyp on one side only (unilateral) raises concern for a different diagnosis (antrochoanal polyp, inverting papilloma, or nasal tumor) and is treated as a reason for urgent ear, nose and throat (ENT) evaluation.

Nasal polyps are classified as part of chronic rhinosinusitis with nasal polyps (CRSwNP) — a distinct inflammatory phenotype from chronic rhinosinusitis (CRS) without polyps. They affect approximately 4% of the general population, with higher rates in adults with asthma (10–15%) and aspirin sensitivity.

Disease Associations

Nasal polyps rarely occur in isolation. Key associated conditions:

• Asthma: 40–70% of CRSwNP patients also have asthma. The relationship is bidirectional — asthma worsens polyp inflammation, and treating polyps improves asthma control. Nasal polyps and asthma are increasingly viewed as manifestations of a unified "united airway disease."
• Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad): The classic combination of asthma + nasal polyps + aspirin/nonsteroidal anti-inflammatory drug (NSAID) sensitivity. Affects approximately 9% of nasal polyp patients. Taking aspirin or ibuprofen triggers bronchospasm, severe nasal symptoms, and flushing within 30–120 minutes. The mechanism involves cyclooxygenase-1 (COX-1) inhibition shunting arachidonic acid toward inflammatory leukotriene production. Aspirin desensitization (gradually increasing aspirin doses under medical supervision) can reduce polyp recurrence and improve asthma in AERD.
• Cystic Fibrosis (CF): Nasal polyps occur in 30–50% of patients with CF. Nasal polyps in a child are a recognised sign of CF, which is tested for with a sweat chloride test.
• Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss): A rare systemic vasculitis with nasal polyps, asthma, and peripheral eosinophilia. Requires systemic treatment with steroids and immunosuppressants.
• Allergic Rhinitis: Allergic inflammation contributes to polyp formation in some patients. However, allergy treatment alone rarely resolves established polyps.

Symptoms

Symptoms develop gradually as polyps grow and obstruct sinus drainage pathways:

• Nasal obstruction: A constant blocked nose that does not respond to decongestants. Severe polyps can cause complete bilateral nasal blockage, forcing mouth breathing.
• Loss of smell (hyposmia/anosmia): Often the most distressing symptom. Olfactory nerves are in the upper nasal cavity — polyp obstruction and eosinophilic inflammation of the olfactory epithelium both contribute. Smell loss is often permanent unless treated early and aggressively. Loss of smell profoundly impacts quality of life, appetite, enjoyment of food, and even safety (inability to smell smoke or gas leaks).
• Chronic runny nose: Watery or mucous rhinorrhea from inflamed sinus mucosa.
• Post-nasal drip: Mucus draining down the back of the throat, causing throat clearing, cough, and irritation.
• Facial pressure and headache: Obstruction of sinus ostia causes pressure buildup. Less dramatic than acute sinusitis pain.
• Snoring and sleep disruption: Nasal obstruction forces mouth breathing during sleep, worsening obstructive sleep apnea (OSA) and sleep quality.
• Loss of taste: Often secondary to smell loss (most "taste" is actually retronasal smell). True taste (sweet, salty, sour, bitter, umami) is usually preserved.

Diagnosis

Diagnosing nasal polyps requires direct visualization — you cannot diagnose them from symptoms alone:

• Anterior rhinoscopy: A general practitioner (GP) or ENT specialist uses a light source and nasal speculum to directly visualize the nasal cavity. Large polyps may be visible as pale gray, translucent, grape-like masses in the middle meatus.
• Nasal endoscopy: A flexible or rigid telescope inserted into the nasal cavity provides much better visualization than rhinoscopy. Standard of care for CRSwNP evaluation. Allows assessment of polyp extent, middle meatus anatomy, and mucosal quality.
• Computed tomography (CT) scan of the sinuses: The gold standard for assessing polyp extent, sinus involvement, and planning surgery. Computed tomography shows characteristic "lacy" opacification of sinuses filled with polyps and mucus. The Lund-Mackay score (0–24) quantifies computed tomography findings. Computed tomography is obtained before surgery.
• Spirometry: For patients with suspected asthma — measures forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and bronchodilator response.
• Serum eosinophil count: Peripheral eosinophilia (>0.3×10⁹/L) supports eosinophilic CRSwNP and predicts better biologic response.
• Immunoglobulin E and allergy testing: Total serum immunoglobulin E and specific allergen skin prick testing or specific immunoglobulin E to assess atopic status.

Medical Treatment

Medical treatment is always attempted before surgery. Goals: reduce polyp size, restore nasal breathing and smell, prevent progression:

• Intranasal corticosteroid sprays (INCS): First-line treatment for all CRSwNP patients. Mometasone, fluticasone, budesonide applied directly to nasal mucosa daily. Reduce polyp size and symptoms in 50–60% of patients. Need to be used indefinitely — stopping leads to recurrence. Correct technique is essential: head tilted forward, spray directed toward the outer wall of the nose (not toward the septum). Minimal systemic absorption at standard doses.
• Short-course oral corticosteroids (prednisone "burst"): Prednisone 0.5–1 mg/kg/day for 5–7 days. Produces rapid, dramatic reduction in polyp size and restoration of smell. However, effects are temporary — polyps typically return within weeks to months. Repeated steroid bursts carry systemic side effects, which is why they are commonly limited to 2–3 courses per year.
• Saline irrigation: Nasal saline rinse (neti pot or squeeze bottle) twice daily removes mucus crusts, humidifies the nasal mucosa, and improves penetration of intranasal steroids. Good evidence for symptom improvement and may reduce polyp burden modestly.
• Treating underlying allergy: Allergen immunotherapy for atopic patients reduces the allergic inflammatory contribution.
• Aspirin desensitization (for AERD patients): Conducted under specialist supervision. Protocols start with low aspirin doses and increase gradually to therapeutic doses, which paradoxically reduces leukotrienes and improves polyp control and asthma in AERD.

Biologic Therapy

Biologics have transformed the treatment of severe CRSwNP that does not respond adequately to steroids and surgery:

• Dupilumab: U.S. Food and Drug Administration-approved for CRSwNP in 2019. Blocks the IL-4 receptor alpha, inhibiting both IL-4 and IL-13 signaling. In pivotal SINUS-24 and SINUS-52 trials, dupilumab reduced polyp size by ~50%, improved nasal obstruction and smell, and reduced need for systemic steroids and repeat surgery. Dramatically improves quality of life. Given as subcutaneous injection every 2 weeks. Also approved for asthma (treats the united airway disease simultaneously).
• Mepolizumab: Anti-IL-5 antibody that depletes eosinophils. U.S. Food and Drug Administration-approved for CRSwNP in 2021. Monthly injections. Good evidence for polyp reduction and symptom improvement. Particularly effective in hypereosinophilic phenotype.
• Benralizumab: Anti-IL-5 receptor antibody that depletes eosinophils more completely than mepolizumab. In the phase 3 ORCHID trial in CRSwNP, benralizumab significantly improved nasal polyp score and nasal blockage score compared with placebo at week 40, but the time to first nasal polyp surgery was not significantly different. Also approved for eosinophilic asthma.
• Tezepelumab: Anti-thymic stromal lymphopoietin (TSLP) antibody. U.S. Food and Drug Administration-approved for CRSwNP in October 2025, following the phase 3 WAYPOINT trial in adults with severe CRSwNP. Also approved for severe asthma.
• Omalizumab: Anti-IgE antibody. U.S. Food and Drug Administration-approved for CRSwNP in 2020. Particularly useful in patients with high total immunoglobulin E and concurrent allergic asthma. Monthly subcutaneous injections.
• Cost considerations: Biologics cost approximately $2,000–$3,000 per month. Insurance coverage requires documented failure of standard treatment (steroids ± surgery). Manufacturer patient assistance programs are available for eligible patients.

Surgery (FESS)

Functional Endoscopic Sinus Surgery (FESS) is the surgical treatment for nasal polyps that do not respond adequately to medical therapy:

• What FESS does: Uses a small endoscope (telescope) inserted through the nostrils — no external incisions. Removes polyps and diseased mucosa, and opens the natural drainage pathways (ostia) of the affected sinuses, allowing improved drainage and better penetration of postoperative topical medications.
• Expected outcomes: Most patients experience significant improvement in nasal breathing, smell, and quality of life for 1–3 years after FESS.
• Recurrence: The major limitation of FESS is high recurrence rate — approximately 50% of patients require revision surgery within 5 years. Polyps grow back because the underlying eosinophilic inflammation persists — surgery removes the mechanical obstruction but does not address the inflammatory root cause.
• Combining surgery with biologics: The most effective strategy for severe CRSwNP is surgery to debulk the polyps and restore drainage, followed by maintenance dupilumab or another biologic to prevent recurrence. This combination significantly reduces revision surgery rates.
• Complications: FESS is generally very safe in experienced hands. Rare but serious complications include cerebrospinal fluid leak, orbital injury, and bleeding.

Recurrence and Long-Term Management

CRSwNP is a chronic disease that requires ongoing management, not a one-time fix:

• Intranasal corticosteroid sprays continued indefinitely after surgery are the single most evidence-based intervention for preventing or delaying recurrence
• Regular ENT follow-up with nasal endoscopy allows early detection of polyp regrowth before symptoms become severe
• In AERD, nonsteroidal anti-inflammatory drugs (NSAIDs), including over-the-counter ibuprofen, can trigger a severe reaction
• Poorly controlled asthma accelerates polyp regrowth
• Daily saline irrigation is used as maintenance
• Biologic therapy is an option for patients with frequent recurrence or severe disease — it does not cure the condition but significantly reduces the frequency and severity of relapses

Key Research Papers

Key peer-reviewed studies on nasal polyps pathophysiology and treatment. Each PMID link opens the study on PubMed.

1. Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012 (EPOS 2012). Rhinol Suppl. 2012;(23):1-298. — PubMed PMID: 22764607
2. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024-1031.e14. — PubMed PMID: 28687232
3. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. — PubMed PMID: 31543428
4. Hamilos DL. Chronic rhinosinusitis: epidemiology and medical management. J Allergy Clin Immunol. 2011;128(4):693-707. — PubMed PMID: 21890184
5. Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc. 1996;17(5):231-236. — PubMed PMID: 8922141
6. Gevaert P, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116. — PubMed PMID: 23021878
7. Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309-1317.e12. — PubMed PMID: 34599979
8. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. — PubMed PMID: 40106374
9. Smith TL, Mendolia-Loffredo S, Loehrl TA, et al. Predictive factors and outcomes in endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope. 2005;115(12):2199-2205. — PubMed PMID: 16369166
10. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis — 2023. Int Forum Allergy Rhinol. 2023;13(4):293-859. — PubMed PMID: 36878860

Curated PubMed topic searches:

1. PubMed: Dupilumab for nasal polyps
2. PubMed: CRSwNP pathogenesis
3. PubMed: FESS surgery
4. PubMed: AERD/Samter's triad
5. PubMed: Anti-IL-5 biologics
6. PubMed: Intranasal steroids
7. PubMed: Smell loss in nasal polyps
8. PubMed: United airway disease

Back to Table of Contents

Connections

• ENT
• Sinusitis
• Sleep Apnea
• Laryngitis and Voice Disorders
• Asthma
• Allergies
• Allergic Rhinitis
• Quercetin
• Vitamin C
• Zinc
• Turmeric
• Inflammatory Bowel Disease

Back to Table of Contents

Featured Videos